CD47 and neoplasm: For instance, CD40 could enhance the phagocytic activity of macrophages recovered by CD47‐SIRPα blockade, and a fusion protein with high affinity to bind CD40 and CD47 performed better than either CD47 blockade or CD40 agonist alone in a mouse CT26 tumor model.360